Patients from 22+ countriesPlan your visit β†’
lutetium-therapy
Patient Journey Β· Phase 2

During treatment.

The active treatment phase spans roughly 6–8 months, depending on whether you're receiving Lu-177 DOTATATE therapy (4 cycles, 8 weeks apart) or Lu-177 PSMA therapy (6 cycles, 6 weeks apart). The rhythm β€” treatment day, brief recovery, normal life, treatment day β€” becomes familiar within the first couple of cycles. Here's what to expect.

Medically reviewedUpdated 16 May 2026
Calm hospital wing hallway with cream floors and natural light

The rhythm of treatment

After the first cycle, most patients settle into a predictable rhythm:

  1. Treatment day β€” outpatient visit, ~4 hours for Lu-177 DOTATATE therapy, ~3 hours for Lu-177 PSMA therapy
  2. Days 1–3 after: follow simple radiation-safety precautions at home
  3. Days 4–7 after: mild fatigue may persist; normal activity returning
  4. Week 2 onward: back to your normal life
  5. Week 5–6 (or 7–8): blood tests, possibly imaging, then next cycle

How progress is tracked between cycles

Blood markers

  • Prostate cancer: PSA before each cycle. A 50% drop ("PSA50") within the first 2–3 cycles is associated with better outcomes.
  • NETs: Chromogranin A (CgA) and 5-HIAA, especially for functional tumors.
  • Both: CBC and kidney function before every cycle to ensure safety.

Imaging

  • Interim PET scan around cycle 3 (for Lu-177 PSMA therapy) or cycle 2–3 (for Lu-177 DOTATATE therapy)
  • CT or MRI for anatomical assessment if needed
  • Bone scan if bone-predominant disease

What if a dose needs to be adjusted?

Your team will check blood counts before every cycle. If platelets, hemoglobin, or neutrophils drop too low, the next cycle may be:

  • Delayed by 1–2 weeks while counts recover
  • Dose-reduced for subsequent cycles
  • Discontinued in rare cases of severe persistent suppression

Most patients complete the planned cycles. Adjustments are part of normal care, not a sign of failure.

What does β€œresponding” look like?

  • Tumor marker drop: PSA or CgA decreasing across cycles
  • Symptom improvement: less pain, better appetite, fewer carcinoid symptoms
  • Imaging response: tumors shrinking or stable
  • Energy: some patients feel better after a few cycles than they have in months β€” the tumor burden was making them sick

Response can take time. Don't panic if your numbers don't change after cycle 1. Many patients see their best response around cycles 3–4.

Frequently asked questions

What if I miss a cycle?

Missing one cycle by a week or two is usually fine. Longer delays may compromise effectiveness. Communicate immediately with your team if illness or scheduling conflicts arise.

Can I travel between cycles?

Yes, most patients can travel. Avoid travel in the first 3–5 days post-cycle (radiation safety) and within a week of expected blood-count nadir (typically 2–4 weeks post-cycle). Bring documentation if flying β€” Lu-177 may set off airport scanners for several weeks.

Can I work between cycles?

Many patients work part-time or full-time. Schedule cycles for a Friday if possible β€” you have the weekend to recover before Monday.

What if I get sick between cycles?

Tell your team. Most routine infections (cold, mild flu) don't require schedule changes, but they need to know. Fever, severe symptoms, or anything serious requires same-day contact with your oncologist.

Have a specific question about your situation?

A free 20-minute conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.